# EDGAR Filing Document

**Accession Number:** 0001141103
**File Stem:** 0001157523-23-000334
**Filing Date:** 2023-2
**Character Count:** 48148
**Document Hash:** f9d70160d4d37aad36faf5972ccf661e
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001157523-23-000334.hdr.sgml**: 20230222

**ACCESSION NUMBER**: 0001157523-23-000334

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20230222

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20230222

**DATE AS OF CHANGE**: 20230222

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** CROSS COUNTRY HEALTHCARE INC
- **CENTRAL INDEX KEY:** 0001141103
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-HELP SUPPLY SERVICES [7363]
- **IRS NUMBER:** 134066229
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-33169
- **FILM NUMBER:** 23653661

**BUSINESS ADDRESS:**
- **STREET 1:** 6551 PARK OF COMMERCE BOULEVARD, N.W.
- **CITY:** BOCA RATON
- **STATE:** FL
- **ZIP:** 33487
- **BUSINESS PHONE:** 8003472264

**MAIL ADDRESS:**
- **STREET 1:** 6551 PARK OF COMMERCE BOULEVARD, N.W.
- **CITY:** BOCA RATON
- **STATE:** FL
- **ZIP:** 33487

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CROSS COUNTRY INC
- **DATE OF NAME CHANGE:** 20010521

**UNITED STATES**

 **SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

### FORM 8-K

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): February 22, 2023

![graphic](cc_logo.jpg)

**Cross Country Healthcare, Inc.**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Delaware**<br>| **0-33169**<br>| **13-4066229**<br>|
| (State or Other Jurisdiction<br> of Incorporation) | (Commission<br> File Number) | (I.R.S. Employer<br> Identification No.) |

---

#### 6551 Park of Commerce Boulevard, N.W., Boca Raton, Florida 33487
(Address of Principal Executive Office) (Zip Code)

(561) 998-2232

(Registrant's telephone number, including area code)

**Not Applicable**

(Former name or former address, if changed since last report)

#### Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol** | **Name of each exchange on which registered** |
| Common stock, par value $0.0001 per share | CCRN | The Nasdaq Stock Market LLC |

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

#### Section 2 – Financial Information

#### Item 2.02&nbsp;&nbsp;&nbsp;&nbsp; Results of Operations and Financial Condition
(a) On February 22, 2023, Cross Country Healthcare, Inc. ("the Company") issued a press release announcing results for the fourth quarter and full year ended December 31, 2022, a copy of which is attached as Exhibit 99.1 to this Current Report on Form 8-K. This information is being furnished under Item 2.02 and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of such section.

#### Section 7 – Regulation FD

#### Item 7.01&nbsp;&nbsp;&nbsp;&nbsp; Regulation FD Disclosure
Incorporated by reference is a press release issued by the Company on February 22, 2023, which is attached hereto as Exhibit 99.1. This information is being furnished under Item 7.01 and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of such section.

#### Section 9 – Financial Statements and Exhibits

#### Item 9.01&nbsp;&nbsp;&nbsp;&nbsp; Financial Statements and Exhibits
(d) Exhibits

---

| | |
|:---|:---|
| Exhibit | Description |
| [99.1](a53334950ex99_1.htm) | [Press Release issued by the Company on February 22, 2022](a53334950ex99_1.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

------

#### SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
|  |  | **CROSS COUNTRY HEALTHCARE, INC.** | **CROSS COUNTRY HEALTHCARE, INC.** |
|  |  | By: | /s/ William J. Burns |
|  |  |  | William J. Burns |
| Dated: | February 22, 2023 |  | Executive Vice President & Chief Financial Officer |

---

## Exhibit 99.1

**Exhibit 99.1**<br>

**** 

<br> # **Cross Country Healthcare Announces Fourth Quarter and Full Year 2022 Financial Results** 
BOCA RATON, Fla.--(BUSINESS WIRE)--February 22, 2023--Cross Country Healthcare, Inc. (the "Company") (Nasdaq: CCRN) today announced financial results for its fourth quarter and full year ended December 31, 2022.

 **SELECTED FINANCIAL INFORMATION:**

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| Dollars are in thousands, except per share amounts  | Q4 2022  | Variance <br> Q4 2022 vs <br> Q4 2021  | Variance <br> Q4 2022 vs <br> Q4 2021  | Variance <br> Q4 2022 vs <br> Q3 2022  | Variance <br> Q4 2022 vs <br> Q3 2022  | Full Year 2022  | Variance <br> 2022 vs <br> 2021  | Variance <br> 2022 vs <br> 2021  |
| Revenue  | $628218  | (2 ) | % | (1 ) | % | $2806609  | 67  | % |
| Gross profit margin\*  | 22.1% | (90 ) | bps  | (50 ) | bps  | 22.4% | —  | bps  |
| Net income attributable to common stockholders  | $38791  | (50 ) | % | 11  | % | $188461  | 43  | % |
| Diluted EPS  | $1.05  | $(1.02 ) |  | $0.12  |  | $5.02  | $1.49  |  |
| Adjusted EBITDA\*  | $57026  | (30 ) | % | (11 ) | % | $301716  | 86  | % |
| Adjusted EBITDA margin\*  | 9.1% | (350 ) | bps  | (90 ) | bps  | 10.8% | 110  | bps  |
| Adjusted EPS\*  | $1.09  | $(0.31 ) |  | $0.02  |  | $5.27  | $2.21  |  |
| Cash flows from operations  | $4320  | 106  | %  | (97 )  | %  | $134050  | 257  | %  |
| \* Refer to accompanying tables and discussion of non-GAAP (Generally Accepted Accounting Principles) financial measures below.  | \* Refer to accompanying tables and discussion of non-GAAP (Generally Accepted Accounting Principles) financial measures below.  | \* Refer to accompanying tables and discussion of non-GAAP (Generally Accepted Accounting Principles) financial measures below.  | \* Refer to accompanying tables and discussion of non-GAAP (Generally Accepted Accounting Principles) financial measures below.  | \* Refer to accompanying tables and discussion of non-GAAP (Generally Accepted Accounting Principles) financial measures below.  | \* Refer to accompanying tables and discussion of non-GAAP (Generally Accepted Accounting Principles) financial measures below.  | \* Refer to accompanying tables and discussion of non-GAAP (Generally Accepted Accounting Principles) financial measures below.  | \* Refer to accompanying tables and discussion of non-GAAP (Generally Accepted Accounting Principles) financial measures below.  | \* Refer to accompanying tables and discussion of non-GAAP (Generally Accepted Accounting Principles) financial measures below.  |

---

 **Business Highlights**

* Double-digit year-over-year annual revenue growth across all segments 

* Launched our proprietary vendor management system Intellify<sup>TM</sup> 

* Strengthened our position in the talent management landscape through the December HireUp acquisition 

* Expanded our locum tenens portfolio through the Mint and Lotus acquisitions 

* Repurchased 1.4 million shares of common stock for $35.3 million in 2022 

* $100 million total optional prepayments on the term loan reducing the balance 58% year over year 

* Hosted our first Investor Day in the third quarter of 2022 

* Added two independent directors with deep technology and healthcare expertise to the Board 

"We are extremely proud of all we accomplished in 2022, from achieving our highest annual revenue and profitability in Company history to transforming Cross Country into a digitally innovative enterprise with comprehensive workforce solutions and an unwavering commitment to clinical excellence," said John A. Martins, President and Chief Executive Officer of Cross Country Healthcare. He continued, "Thanks to the investments in our people and technology, as well as strategic acquisitions, we are fundamentally a different organization today and I believe we are well-positioned for continued success."

------

Fourth quarter consolidated revenue was $628.2 million, a slight decrease from the prior year and prior quarter. Consolidated gross profit margin was 22.1%, down 90 basis points year-over-year and 50 basis points sequentially. Net income attributable to common stockholders was $38.8 million compared to $77.6 million in the prior year and $34.8 million in the prior quarter. Diluted earnings per share (EPS) was $1.05 compared to $2.07 in the prior year and $0.93 in the prior quarter. Adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) was $57.0 million or 9.1% of revenue, as compared with $80.9 million or 12.6% of revenue in the prior year, and $63.8 million or 10.0% of revenue in the prior quarter. Adjusted EPS was $1.09 compared to $1.40 in the prior year and $1.07 in the prior quarter.

For the year ended December 31, 2022, consolidated revenue was $2.8 billion, an increase of 67% year-over-year. Consolidated gross profit margin was 22.4%, consistent with the prior year. Net income attributable to common stockholders was $188.5 million, or 5.02 per diluted share, compared to $132.0 million, or $3.53 per diluted share, in the prior year. Adjusted EBITDA was $301.7 million or 10.8% of revenue, as compared with $162.1 million or 9.7% of revenue in the prior year. Adjusted EPS was $5.27 compared to $3.06 in the prior year.

 **Quarterly Business Segment Highlights**

 *Nurse and Allied Staffing*

Revenue was $591.1 million, a decrease of 5% year-over-year and 3% sequentially. Contribution income was $69.9 million, a decrease from $92.4 million in the prior year and $77.8 million in the prior quarter. Average field contract personnel on a full-time equivalent (FTE) basis were 12,447 as compared with 11,520 in the prior year and 12,524 in the prior quarter. Revenue per FTE per day was $510 compared to $582 in the prior year and $526 in the prior quarter. The increase in average number of FTEs as compared to the prior year was primarily due to headcount growth in nurse and allied. As expected, average bill rates were down sequentially in the low single digits.

 *Physician Staffing*

Revenue was $37.1 million, an increase of 84% year-over-year and 56% sequentially. Contribution income was $1.7 million, an increase from $1.4 million in the prior year and $0.8 million in the prior quarter. Total days filled were 21,335 as compared with 12,739 in the prior year and 13,219 in the prior quarter. Revenue per day filled was $1,740 as compared with $1,588 in the prior year and $1,803 in the prior quarter. The increase in revenue was primarily due to an increase in volume in several specialties. The increase in contribution income was driven by higher revenue, partially offset by higher direct costs.

 **Cash Flow and Balance Sheet Highlights**

Cash flow provided by operations for the quarter was $4.3 million, primarily due to a slowdown in collections in the fourth quarter. For the year ended December 31, 2022, cash flow provided by operations was $134.1 million compared to cash flow used in operations of $85.6 million in the prior year.

During the fourth quarter, the Company repurchased and retired a total of 0.4 million shares of the Company's common stock for an aggregate price of $10.9 million, at an average market price of $31.23 per share. As of December 31, 2022, the Company had 36.3 million unrestricted shares outstanding and $76.2 million remaining for share repurchase. In November 2022, the Company entered into a Rule 10b5-1 repurchase plan to allow for share repurchases during the Company's blackout periods.

------

On October 3, 2022, the Company acquired Mint Medical Physician Staffing, LP and Lotus Medical Staffing LLC. The purchase price included $27.0 million in cash and $3.6 million in shares of the Company's common stock. The Company acquired HireUp Leadership, Inc. on December 13, 2022. The purchase price included $6.0 million in cash and $0.8 million in shares of the Company's common stock. In addition to its scheduled payments, on June 23, 2022 and October 26, 2022, the Company made optional prepayments of $50.0 million, totaling $100.0 million, on its term loan to reduce interest costs.

At December 31, 2022, the Company had $3.6 million in cash and cash equivalents and $73.9 million principal balance on its term loan, with $76.8 million of borrowings drawn under its revolving senior secured asset-based credit facility (ABL), and $18.2 million of letters of credit outstanding. As of December 31, 2022, borrowing base availability under the ABL was $300.0 million, with $205.0 million of excess availability.

 **Outlook for First Quarter 2023**

The guidance below applies only to management's expectations for the first quarter of 2023.

---

| | | | |
|:---|:---|:---|:---|
|  | Q1 2023 Range  | | |
|  | Q1 2023 Range  | Year-over-Year <br>Change  | Sequential <br>Change  |
| Revenue  | $590 million - $600 million  | (25)% - (24)%  | (6)% - (4)%  |
| Adjusted EBITDA\*  | $44.0 million - $49.0 million  | (55)% - (50)%  | (23)% - (14)%  |
| Adjusted EPS\*  | $0.70 - $0.80  | $(1.00) - $(0.90)  | $(0.39) - $(0.29)  |

---

\* Refer to discussion of non-GAAP financial measures below.

The above estimates are based on current management expectations and, as such, are forward-looking and actual results may differ materially. The above ranges do not include the potential impact of any future divestitures, mergers, acquisitions, or other business combinations, changes in debt structure, or future significant share repurchases. We reaffirm our 2023 annual targets of a minimum $2.2 billion in revenue and $200 million in Adjusted EBITDA.

See accompanying non-GAAP financial measures and tables below.

 **INVITATION TO CONFERENCE CALL**

The Company will hold its quarterly conference call on Wednesday, February 22, 2023, at 5:00 P.M. Eastern Time to discuss its fourth quarter and full year 2022 financial results. This call will be a live webcast and can be accessed on the Company's website at ir.crosscountryhealthcare.com or by dialing 888-566-1290 from anywhere in the U.S. or by dialing 773-799-3776 from non-U.S. locations - Passcode: Cross Country. A replay of the webcast will be available from February 22nd through March 8th on the Company's website and a replay of the conference call will be available by telephone by calling 800-813-5529 from anywhere in the U.S. or 203-369-3826 from non-U.S. locations - Passcode: 9863.

------

 **ABOUT CROSS COUNTRY HEALTHCARE**

Cross Country Healthcare, Inc. is a leading tech-enabled workforce solutions and advisory firm with 36 years of industry experience and insight. We solve complex labor-related challenges for customers while providing high-quality outcomes and exceptional patient care. As a multi-year Best of Staffing<sup>®</sup> award winner, we are committed to an exceptionally high level of service to our clients and our homecare, education, and clinical and non-clinical healthcare professionals. Our locum tenens line of business, Cross Country Locums, has been certified by the National Committee for Quality Assurance (NCQA), the leader in healthcare accreditation, since 2001. We are the first publicly traded staffing firm to obtain The Joint Commission Certification, which we still hold with a Letter of Distinction. Cross Country Healthcare is rated as the top staffing and recruiting employer for women by InHerSights, and Certified™ by Great Place to Work<sup>®</sup>. For three consecutive years, we have received the Top Workplaces USA award from Energage and have also been recognized with the Top Workplaces Award for Diversity, Equity & Inclusion Practices and the Top Workplaces Awards for Innovation and Leadership. We have recently been awarded the Women Executive Leadership Elevate Award, recognizing gender diversity in our Boardroom. We have a history of investing in diversity, equality, and inclusion as a key component of the organization's overall corporate social responsibility program, closely aligned with its core values to create a better future for its people, communities, and its stockholders.

Copies of this and other press releases, as well as additional information about the Company, can be accessed online at ir.crosscountryhealthcare.com. Stockholders and prospective investors can also register to automatically receive the Company's press releases, filings with the Securities and Exchange Commission (SEC), and other notices by e-mail.

 **NON-GAAP FINANCIAL MEASURES**

This press release and the accompanying financial statement tables reference non-GAAP financial measures, such as gross profit margin, adjusted EBITDA, and adjusted EPS. Such non-GAAP financial measures are provided as additional information and should not be considered substitutes for, or superior to, financial measures calculated in accordance with U.S. GAAP. Such non-GAAP financial measures are provided for consistency and comparability to prior year results; furthermore, management believes they are useful to investors when evaluating the Company's performance as they exclude certain items that management believes are not indicative of the Company's future operating performance. Pro forma measures, if applicable, are adjusted to include the results of our acquisitions, and exclude the results of divestments, as if the transactions occurred in the beginning of the periods mentioned. Such non-GAAP financial measures may differ materially from the non-GAAP financial measures used by other companies. The financial statement tables that accompany this press release include a reconciliation of each non-GAAP financial measure to the most directly comparable U.S. GAAP financial measure and a more detailed discussion of each financial measure; as such, the financial statement tables should be read in conjunction with the presentation of these non-GAAP financial measures.

------

In addition, forward-looking adjusted EBITDA and adjusted EPS for fiscal 2023 exclude potential charges or gains that may be recorded during the fiscal year, including among other things, the potential impact of any future divestitures, mergers, acquisitions, or other business combinations, changes in debt structure, or future significant share repurchases. We have not attempted to provide reconciliations of such forward-looking non-GAAP earnings guidance to the comparable GAAP measure, as permitted by Item 10(e)(1)(i)(B) of Regulation S-K, because the impact and timing of these potential charges or gains is inherently uncertain and difficult to predict and is unavailable without unreasonable efforts. In addition, the Company believes such reconciliations would imply a degree of precision and certainty that could be confusing to investors. Such items could have a substantial impact on GAAP measures of our financial performance.

 **FORWARD LOOKING STATEMENTS**

 *Although we believe that these statements are based upon reasonable assumptions, we cannot guarantee future results and readers are cautioned not to place undue reliance on these forward-looking statements, which reflect management's opinions only as of the date of this press release. There can be no assurance that (i) we have correctly measured or identified all of the factors affecting our business or the extent of these factors' likely impact, (ii) the available information with respect to these factors on which such analysis is based is complete or accurate, (iii) such analysis is correct, or (iv) our strategy, which is based in part on this analysis, will be successful. Except as may be required by law, the Company undertakes no obligation to update or revise forward-looking statements. All references to "the Company", "we", "us", "our", or "Cross Country" in this press release mean Cross Country Healthcare, Inc. and its consolidated subsidiaries.*

------

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Cross Country Healthcare, Inc.**  | **Cross Country Healthcare, Inc.**  | **Cross Country Healthcare, Inc.**  | **Cross Country Healthcare, Inc.**  | **Cross Country Healthcare, Inc.**  | **Cross Country Healthcare, Inc.**  |
| **Consolidated Statements of Operations**  | **Consolidated Statements of Operations**  | **Consolidated Statements of Operations**  | **Consolidated Statements of Operations**  | **Consolidated Statements of Operations**  | **Consolidated Statements of Operations**  |
| **(Unaudited, amounts in thousands, except per share data)**  | **(Unaudited, amounts in thousands, except per share data)**  | **(Unaudited, amounts in thousands, except per share data)**  | **(Unaudited, amounts in thousands, except per share data)**  | **(Unaudited, amounts in thousands, except per share data)**  | **(Unaudited, amounts in thousands, except per share data)**  |
|  | Three Months Ended  | Three Months Ended  | Three Months Ended  | Year Ended  | Year Ended  |
|  | December 31,  | December 31,  | September 30,  | December 31,  | December 31,  |
|  | 2022  | 2021  | 2022  | 2022  | 2021  |
| Revenue from services  | $628218  | $640679  | $636098  | $2806609  | $1676652  |
| Operating expenses:  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; Direct operating expenses  | 489276  | 493529  | 492553  | 2178923  | 1301653  |
| &nbsp;&nbsp;&nbsp;&nbsp; Selling, general and administrative expenses  | 81171  | 65774  | 80216  | 324209  | 215292  |
| &nbsp;&nbsp;&nbsp;&nbsp; Bad debt expense  | 2947  | 2372  | 1101  | 9609  | 4783  |
| &nbsp;&nbsp;&nbsp;&nbsp; Depreciation and amortization  | 3162  | 2720  | 3214  | 12576  | 9852  |
| &nbsp;&nbsp;&nbsp;&nbsp; Acquisition and integration-related costs  | 196  | 83  | 490  | 726  | 1068  |
| &nbsp;&nbsp;&nbsp;&nbsp; Restructuring costs  | 2  | 239  | 2493  | 1861  | 2630  |
| &nbsp;&nbsp;&nbsp;&nbsp; Impairment charges  | —  | —  | 3856  | 5597  | 2070  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total operating expenses  | 576754  | 564717  | 583923  | 2533501  | 1537348  |
| Income from operations  | 51464  | 75962  | 52175  | 273108  | 139304  |
| Other expenses (income):  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; Interest expense  | 3515  | 2817  | 3498  | 14391  | 6866  |
| &nbsp;&nbsp;&nbsp;&nbsp; Loss on early extinguishment of debt  | 1816  | —  | —  | 3728  | —  |
| &nbsp;&nbsp;&nbsp;&nbsp; Other income, net  | (217 )  | (154 )  | (27 )  | (1336 )  | (770 )  |
| Income before income taxes  | 46350  | 73299  | 48704  | 256325  | 133208  |
| Income tax expense (benefit)  | 7559  | (4274 )  | 13911  | 67864  | 1206  |
| Net income attributable to common stockholders  | $38791  | $77573  | $34793  | $188461  | $132002  |
| Net income per share attributable to common stockholders - Basic  | $1.06  | $2.10  | $0.94  | $5.09  | $3.60  |
| Net income per share attributable to common stockholders - Diluted  | $1.05  | $2.07  | $0.93  | $5.02  | $3.53  |
| Weighted average common shares outstanding:  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; Basic  | 36455  | 36974  | 37101  | 37012  | 36689  |
| &nbsp;&nbsp;&nbsp;&nbsp; Diluted  | 36926  | 37736  | 37492  | 37536  | 37392  |

---

------

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Cross Country Healthcare, Inc.**  | **Cross Country Healthcare, Inc.**  | **Cross Country Healthcare, Inc.**  | **Cross Country Healthcare, Inc.**  | **Cross Country Healthcare, Inc.**  | **Cross Country Healthcare, Inc.**  |
| **Reconciliation of Non-GAAP Financial Measures**  | **Reconciliation of Non-GAAP Financial Measures**  | **Reconciliation of Non-GAAP Financial Measures**  | **Reconciliation of Non-GAAP Financial Measures**  | **Reconciliation of Non-GAAP Financial Measures**  | **Reconciliation of Non-GAAP Financial Measures**  |
| **(Unaudited, amounts in thousands)**  | **(Unaudited, amounts in thousands)**  | **(Unaudited, amounts in thousands)**  | **(Unaudited, amounts in thousands)**  | **(Unaudited, amounts in thousands)**  | **(Unaudited, amounts in thousands)**  |
|  | Three Months Ended  | Three Months Ended  | Three Months Ended  | Year Ended  | Year Ended  |
|  | December 31,  | December 31,  | September 30,  | December 31,  | December 31,  |
|  | 2022  | 2021  | 2022  | 2022  | 2021  |
| **Adjusted EBITDA:<sup>a</sup>**  |  |  |  |  |  |
| Net income attributable to common stockholders  | $38791  | $77573  | $34793  | $188461  | $132002  |
| &nbsp;&nbsp;&nbsp;&nbsp; Interest expense  | 3515  | 2817  | 3498  | 14391  | 6866  |
| &nbsp;&nbsp;&nbsp;&nbsp; Income tax expense (benefit)<sup>b</sup>  | 7559  | (4274 ) | 13911  | 67864  | 1206  |
| &nbsp;&nbsp;&nbsp;&nbsp; Depreciation and amortization  | 3162  | 2720  | 3214  | 12576  | 9852  |
| &nbsp;&nbsp;&nbsp;&nbsp; Acquisition and integration-related costs<sup>c</sup>  | 196  | 83  | 490  | 726  | 1068  |
| &nbsp;&nbsp;&nbsp;&nbsp; Restructuring costs<sup>d</sup>  | 2  | 239  | 2493  | 1861  | 2630  |
| &nbsp;&nbsp;&nbsp;&nbsp; Legal settlements and fees<sup>e</sup>  | —  | 12  | —  | —  | (1141 ) |
| &nbsp;&nbsp;&nbsp;&nbsp; Impairment charges<sup>f</sup>  | —  | —  | 3856  | 5597  | 2070  |
| &nbsp;&nbsp;&nbsp;&nbsp; Loss on disposal of fixed assets  | 19  | 159  | —  | 44  | 219  |
| &nbsp;&nbsp;&nbsp;&nbsp; Loss on early extinguishment of debt<sup>g</sup>  | 1816  | —  | —  | 3728  | —  |
| &nbsp;&nbsp;&nbsp;&nbsp; Gain on lease termination<sup>h</sup>  | (231 ) | (308 ) | (9 ) | (1325 ) | (542 ) |
| &nbsp;&nbsp;&nbsp;&nbsp; Other income, net  | (4 ) | (5 ) | (19 ) | (55 ) | (447 ) |
| &nbsp;&nbsp;&nbsp;&nbsp; Equity compensation  | 2187  | 1637  | 1491  | 7393  | 6894  |
| &nbsp;&nbsp;&nbsp;&nbsp; Applicant tracking system costs<sup>i</sup>  | 14  | 280  | 74  | 455  | 1376  |
| Adjusted EBITDA<sup>a</sup>  | $57026  | $80933  | $63792  | $301716  | $162053  |
| Adjusted EBITDA margin<sup>a</sup>  | 9.1 <br> %  | 12.6 <br> %  | 10.0 <br> %  | 10.8 <br> %  | 9.7 <br> %  |
| **Adjusted EPS:<sup>j</sup>**  |  |  |  |  |  |
| Numerator:  |  |  |  |  |  |
| Net income attributable to common stockholders  | $38791  | $77573  | $34793  | $188461  | $132002  |
| Non-GAAP adjustments - pretax:  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; Acquisition and integration-related costs<sup>c</sup>  | 196  | 83  | 490  | 726  | 1068  |
| &nbsp;&nbsp;&nbsp;&nbsp; Restructuring costs<sup>d</sup>  | 2  | 239  | 2493  | 1861  | 2630  |
| &nbsp;&nbsp;&nbsp;&nbsp; Legal settlements and fees<sup>e</sup>  | —  | 12  | —  | —  | (1141 ) |
| &nbsp;&nbsp;&nbsp;&nbsp; Impairment charges<sup>f</sup>  | —  | —  | 3856  | 5597  | 2070  |
| &nbsp;&nbsp;&nbsp;&nbsp; Applicant tracking system costs<sup>i</sup>  | 14  | 280  | 74  | 455  | 1376  |
| &nbsp;&nbsp;&nbsp;&nbsp; Loss on early extinguishment of debt<sup>g</sup>  | 1816  | —  | —  | 3728  | —  |
| &nbsp;&nbsp;&nbsp;&nbsp; Nonrecurring income tax adjustments<sup>k</sup>  | —  | (25188 ) | —  | —  | (23246 ) |
| Tax impact of non-GAAP adjustments  | (519 )  | (158 )  | (1802 )  | (3198 )  | (172 )  |
| Adjusted net income attributable to common stockholders - non-GAAP  | $40300  | $52841  | $39904  | $197630  | $114587  |
| Denominator:  |  |  |  |  |  |
| Weighted average common shares - basic, GAAP  | 36455  | 36974  | 37101  | 37012  | 36689  |
| Dilutive impact of share-based payments  | 471  | 762  | 391  | 524  | 703  |
| Adjusted weighted average common shares - diluted, non-GAAP  | 36926  | 37736  | 37492  | 37536  | 37392  |
| Reconciliation:  |  |  |  |  |  |
| Diluted EPS, GAAP  | $1.05  | $2.07  | $0.93  | $5.02  | $3.53  |
| Non-GAAP adjustments - pretax:  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; Acquisition and integration-related costs<sup>c</sup>  | 0.01  | —  | 0.01  | 0.02  | 0.03  |
| &nbsp;&nbsp;&nbsp;&nbsp; Restructuring costs<sup>d</sup>  | —  | —  | 0.07  | 0.05  | 0.06  |
| &nbsp;&nbsp;&nbsp;&nbsp; Legal settlements and fees<sup>e</sup>  | —  | —  | —  | —  | (0.02 ) |
| &nbsp;&nbsp;&nbsp;&nbsp; Impairment charges<sup>f</sup>  | —  | —  | 0.10  | 0.15  | 0.05  |
| &nbsp;&nbsp;&nbsp;&nbsp; Applicant tracking system costs<sup>i</sup>  | —  | —  | —  | 0.01  | 0.03  |
| &nbsp;&nbsp;&nbsp;&nbsp; Loss on early extinguishment of debt<sup>g</sup>  | 0.05  | —  | —  | 0.10  | —  |
| &nbsp;&nbsp;&nbsp;&nbsp; Nonrecurring income tax adjustments<sup>k</sup>  | —  | (0.67 ) | —  | —  | (0.62 ) |
| Tax impact of non-GAAP adjustments  | (0.02 )  | —  | (0.04 )  | (0.08 )  | —  |
| Adjusted EPS, non-GAAP<sup>j</sup>  | $1.09  | $1.40  | $1.07  | $5.27  | $3.06  |

---

------

---

| | | |
|:---|:---|:---|
| **Cross Country Healthcare, Inc.**  | **Cross Country Healthcare, Inc.**  | **Cross Country Healthcare, Inc.**  |
| **Consolidated Balance Sheets**  | **Consolidated Balance Sheets**  | **Consolidated Balance Sheets**  |
| **(Unaudited, amounts in thousands)**  | **(Unaudited, amounts in thousands)**  | **(Unaudited, amounts in thousands)**  |
|  | December 31,  | December 31,  |
|  | 2022  | 2021  |
| **Assets**  |  |  |
| Current assets:  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; Cash and cash equivalents  | $3604  | $1036  |
| &nbsp;&nbsp;&nbsp;&nbsp; Accounts receivable, net  | 641611  | 493910  |
| &nbsp;&nbsp;&nbsp;&nbsp; Income taxes receivable  | 10915  | —  |
| &nbsp;&nbsp;&nbsp;&nbsp; Prepaid expenses  | 11067  | 7648  |
| &nbsp;&nbsp;&nbsp;&nbsp; Insurance recovery receivable  | 7434  | 5041  |
| &nbsp;&nbsp;&nbsp;&nbsp; Other current assets  | 1042  | 638  |
| Total current assets  | 675673  | 508273  |
| Property and equipment, net  | 19662  | 15833  |
| Operating lease right-of-use assets  | 3254  | 7488  |
| Goodwill  | 163268  | 119490  |
| Other intangible assets, net  | 44723  | 48244  |
| Non-current deferred tax assets  | 7092  | 11525  |
| Non-current insurance recovery receivable  | 23058  | 13998  |
| Other non-current assets  | 11109  | 7958  |
| Total assets  | $947839  | $732809  |
| **Liabilities and Stockholders' Equity**  |  |  |
| Current liabilities:  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; Accounts payable and accrued expenses  | $185507  | $109753  |
| &nbsp;&nbsp;&nbsp;&nbsp; Accrued compensation and benefits  | 72605  | 65580  |
| &nbsp;&nbsp;&nbsp;&nbsp; Current portion of debt  | —  | 4176  |
| &nbsp;&nbsp;&nbsp;&nbsp; Operating lease liabilities - current  | 4132  | 4090  |
| &nbsp;&nbsp;&nbsp;&nbsp; Income tax payable  | 20  | 7307  |
| &nbsp;&nbsp;&nbsp;&nbsp; Current portion of earnout liability  | 7500  | 7500  |
| &nbsp;&nbsp;&nbsp;&nbsp; Other current liabilities  | 1876  | 1364  |
| Total current liabilities  | 271640  | 199770  |
| Non-current debt, less current portion  | 148735  | 176366  |
| Operating lease liabilities - non-current  | 4880  | 10853  |
| Non-current accrued claims  | 35881  | 25314  |
| Non-current earnout liability  | 18000  | 9000  |
| Uncertain tax positions - non-current  | 7646  | 8994  |
| Other non-current liabilities  | 3838  | 4984  |
| Total liabilities  | 490620  | 435281  |
| Commitments and contingencies  |  |  |
| Stockholders' equity:  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; Common stock  | 4  | 4  |
| &nbsp;&nbsp;&nbsp;&nbsp; Additional paid-in capital  | 292876  | 321552  |
| &nbsp;&nbsp;&nbsp;&nbsp; Accumulated other comprehensive loss  | (1387 ) | (1293 ) |
| &nbsp;&nbsp;&nbsp;&nbsp; Retained earnings (accumulated deficit)  | 165726  | (22735 )  |
| Total stockholders' equity  | 457219  | 297528  |
| Total liabilities and stockholders' equity  | $947839  | $732809  |

---

------

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **Cross Country Healthcare, Inc.**  | **Cross Country Healthcare, Inc.**  | **Cross Country Healthcare, Inc.**  | **Cross Country Healthcare, Inc.**  | **Cross Country Healthcare, Inc.**  | **Cross Country Healthcare, Inc.**  | **Cross Country Healthcare, Inc.**  | **Cross Country Healthcare, Inc.**  | **Cross Country Healthcare, Inc.**  |
| **Segment Data<sup>l</sup>**  | **Segment Data<sup>l</sup>**  | **Segment Data<sup>l</sup>**  | **Segment Data<sup>l</sup>**  | **Segment Data<sup>l</sup>**  | **Segment Data<sup>l</sup>**  | **Segment Data<sup>l</sup>**  | **Segment Data<sup>l</sup>**  | **Segment Data<sup>l</sup>**  |
| **(Unaudited, amounts in thousands)**  | **(Unaudited, amounts in thousands)**  | **(Unaudited, amounts in thousands)**  | **(Unaudited, amounts in thousands)**  | **(Unaudited, amounts in thousands)**  | **(Unaudited, amounts in thousands)**  | **(Unaudited, amounts in thousands)**  | **(Unaudited, amounts in thousands)**  | **(Unaudited, amounts in thousands)**  |
|  | Three Months Ended  | Three Months Ended  | Three Months Ended  | Three Months Ended  | Three Months Ended  | Three Months Ended  | Year-over <br> Year  | Sequential  |
|  | December 31,  | % of  | December 31,  | % of  | September 30,  | % of  | % change  | % change  |
|  | 2022  | Total  | 2021  | Total  | 2022  | Total  | Fav (Unfav)  | Fav (Unfav)  |
| Revenue from services:  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; Nurse and Allied Staffing  | $591090  | 94% | $620446  | 97% | $612270  | 96% | (5 )% | (3 )% |
| &nbsp;&nbsp;&nbsp;&nbsp; Physician Staffing  | 37128  | 6% | 20233  | 3% | 23828  | 4% | 84% | 56% |
|  | $628218  | 100% | $640679  | 100% | $636098  | 100% | (2 )% | (1 )% |
| Contribution income:<sup>m</sup>  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; Nurse and Allied Staffing  | $69941  |  | $92392  |  | $77838  |  | (24 )% | (10 )% |
| &nbsp;&nbsp;&nbsp;&nbsp; Physician Staffing  | 1686  |  | 1428  |  | 837  |  | 18% | 101% |
|  | 71627  |  | 93820  |  | 78675  |  | (24 )% | (9 )% |
| &nbsp;&nbsp;&nbsp;&nbsp; Corporate overhead<sup>n</sup>  | 16803  |  | 14816  |  | 16447  |  | (13 )% | (2 )% |
| &nbsp;&nbsp;&nbsp;&nbsp; Depreciation and amortization  | 3162  |  | 2720  |  | 3214  |  | (16 )% | 2% |
| &nbsp;&nbsp;&nbsp;&nbsp; Acquisition and integration-related costs<sup>c</sup>  | 196  |  | 83  |  | 490  |  | (136 )% | 60% |
| &nbsp;&nbsp;&nbsp;&nbsp; Restructuring costs<sup>d</sup>  | 2  |  | 239  |  | 2493  |  | 99% | 100% |
| &nbsp;&nbsp;&nbsp;&nbsp; Impairment charges<sup>f</sup>  | —  |  | —  |  | 3856  |  | — % | 100% |
| Income from operations  | $51464  |  | $75962  |  | $52175  |  | (32 )% | (1 )% |
|  | Year Ended  | Year Ended  | Year Ended  | Year Ended  |  |  | Year-over <br> Year  |  |
|  | December 31,  | % of  | December 31,  | % of  |  |  | % change  |  |
|  | 2022  | Total  | 2021  | Total  |  |  | Fav (Unfav)  |  |
| Revenue from services:  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; Nurse and Allied Staffing  | $2700383  | 96% | $1605781  | 96% |  |  | 68% |  |
| &nbsp;&nbsp;&nbsp;&nbsp; Physician Staffing  | 106226  | 4% | 70871  | 4% |  |  | 50% |  |
|  | $2806609  | 100% | $1676652  | 100% |  |  | 67% |  |
| Contribution income:<sup>m</sup>  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; Nurse and Allied Staffing  | $355447  |  | $205738  |  |  |  | 73% |  |
| &nbsp;&nbsp;&nbsp;&nbsp; Physician Staffing  | 5508  |  | 4328  |  |  |  | 27% |  |
|  | 360955  |  | 210066  |  |  |  | 72% |  |
| &nbsp;&nbsp;&nbsp;&nbsp; Corporate overhead<sup>n</sup>  | 67087  |  | 55142  |  |  |  | (22 )% |  |
| &nbsp;&nbsp;&nbsp;&nbsp; Depreciation and amortization  | 12576  |  | 9852  |  |  |  | (28 )% |  |
| &nbsp;&nbsp;&nbsp;&nbsp; Acquisition and integration-related costs<sup>c</sup>  | 726  |  | 1068  |  |  |  | 32% |  |
| &nbsp;&nbsp;&nbsp;&nbsp; Restructuring costs<sup>d</sup>  | 1861  |  | 2630  |  |  |  | 29% |  |
| &nbsp;&nbsp;&nbsp;&nbsp; Impairment charges<sup>f</sup>  | 5597  |  | 2070  |  |  |  | (170 )% |  |
| Income from operations  | $273108  |  | $139304  |  |  |  | 96% |  |

---

------

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Cross Country Healthcare, Inc.**  | **Cross Country Healthcare, Inc.**  | **Cross Country Healthcare, Inc.**  | **Cross Country Healthcare, Inc.**  | **Cross Country Healthcare, Inc.**  | **Cross Country Healthcare, Inc.**  |
| **Summary Condensed Consolidated Statements of Cash Flows**  | **Summary Condensed Consolidated Statements of Cash Flows**  | **Summary Condensed Consolidated Statements of Cash Flows**  | **Summary Condensed Consolidated Statements of Cash Flows**  | **Summary Condensed Consolidated Statements of Cash Flows**  | **Summary Condensed Consolidated Statements of Cash Flows**  |
| **(Unaudited, amounts in thousands)**  | **(Unaudited, amounts in thousands)**  | **(Unaudited, amounts in thousands)**  | **(Unaudited, amounts in thousands)**  | **(Unaudited, amounts in thousands)**  | **(Unaudited, amounts in thousands)**  |
|  | Three Months Ended  | Three Months Ended  | Three Months Ended  | Year Ended  | Year Ended  |
|  | December 31,  | December 31,  | September 30,  | December 31,  | December 31,  |
|  | 2022  | 2021  | 2022  | 2022  | 2021  |
| Net cash provided by (used in) operating activities  | $4320  | $(73365 ) | $140627  | $134050  | $(85618 ) |
| Net cash used in investing activities  | (37111 ) | (4686 ) | (2915 ) | (43874 ) | (34046 ) |
| Net cash provided by (used in) financing activities  | 6075  | 78226  | (107661 ) | (87599 ) | 119094  |
| Effect of exchange rate changes on cash  | —  | 19  | (10 )  | (9 )  | 6  |
| Change in cash and cash equivalents  | (26716 ) | 194  | 30041  | 2568  | (564 ) |
| Cash and cash equivalents at beginning of period  | 30320  | 842  | 279  | 1036  | 1600  |
| Cash and cash equivalents at end of period  | $3604  | $1036  | $30320  | $3604  | $1036  |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Cross Country Healthcare, Inc.**  | **Cross Country Healthcare, Inc.**  | **Cross Country Healthcare, Inc.**  | **Cross Country Healthcare, Inc.**  | **Cross Country Healthcare, Inc.**  | **Cross Country Healthcare, Inc.**  |
| **Other Financial Data**  | **Other Financial Data**  | **Other Financial Data**  | **Other Financial Data**  | **Other Financial Data**  | **Other Financial Data**  |
| **(Unaudited)**  | **(Unaudited)**  | **(Unaudited)**  | **(Unaudited)**  | **(Unaudited)**  | **(Unaudited)**  |
|  | Three Months Ended  | Three Months Ended  | Three Months Ended  | Year Ended  | Year Ended  |
|  | December 31,  | December 31,  | September 30,  | December 31,  | December 31,  |
|  | 2022  | 2021  | 2022  | 2022  | 2021  |
| Consolidated gross profit margin<sup>o</sup>  | 22.1% | 23.0% | 22.6% | 22.4% | 22.4% |
| <u>Nurse and Allied Staffing statistical data:</u>  |  |  |  |  |  |
| FTEs<sup>p</sup>  | 12447  | 11520  | 12524  | 12980  | 8679  |
| Average Nurse and Allied Staffing revenue per FTE per day<sup>q</sup>  | $510  | $582  | $526  | $565  | $503  |
| <u>Physician Staffing statistical data:</u>  |  |  |  |  |  |
| Days filled<sup>r</sup>  | 21335  | 12739  | 13219  | 60038  | 44169  |
| Revenue per day filled<sup>s</sup>  | $1740  | $1588  | $1803  | $1769  | $1605  |

---

------

(a) <br> Adjusted EBITDA, a non-GAAP financial measure, is defined as net income (loss) attributable to common stockholders before interest expense, income tax expense (benefit), depreciation and
 amortization, acquisition and integration-related costs, restructuring (benefits) costs, legal settlements and fees, impairment charges, gain or loss on derivative, loss on early extinguishment of debt, gain or loss on disposal of fixed
 assets, gain or loss on lease termination, gain or loss on sale of business, other expense (income), net, equity compensation, and applicant tracking system costs. Adjusted EBITDA is not and should not be considered a measure of
 financial performance under GAAP. Management presents Adjusted EBITDA because it believes that Adjusted EBITDA is a useful supplement to net income attributable to common stockholders as an indicator of operating performance. Management
 uses Adjusted EBITDA for planning purposes and as one performance measure in its incentive programs for certain members of its management team. Adjusted EBITDA, as defined, closely matches the operating measure as defined by the
 Company's credit facilities. Adjusted EBITDA Margin is calculated by dividing Adjusted EBITDA by the Company's consolidated revenue.

(b) <br> The release of the majority of the valuation allowance on deferred tax assets as of December 31, 2021 resulted in an income tax benefit of $4.3 million for the three months ended December
 31, 2021 and income tax expense of $1.2 million for the year ended December 31, 2021. The release resulted in increased income tax expense in 2022.

(c) <br> Acquisition and integration-related costs in 2022 included costs for legal and advisory fees for the Mint and Lotus acquisition that closed in October 2022 and the HireUp acquisition that
 closed in December 2022. Costs in 2021 included costs for legal and advisory fees, as well as integration costs, for the Workforce Solutions Group (WSG) acquisition that closed in the second quarter of 2021, and legal and professional
 fees for the Selected, Inc. (Selected) acquisition that closed in the fourth quarter of 2021.

(d) <br> Restructuring costs were primarily comprised of employee termination costs, lease-related exit costs, and reorganization costs as part of planned cost savings initiatives. Amounts for the
 year ended December 31, 2022 included a benefit associated with the early termination of the lease for one of the Company's corporate offices in the second quarter, which was previously restructured.

(e) <br> Legal settlements and fees included legal settlement charges as presented on the consolidated statements of operations, as well as legal fees pertaining to non-operational legal matters
 outside the normal course of operations, which are included in selling, general and administrative expenses. For the year ended December 31, 2021, legal settlements and fees resulted in a net benefit of $1.1 million due to a recovery in
 the third quarter of $1.6 million.

(f) <br> Impairment charges for the year ended December 31, 2022 were comprised of $3.7 million related to right-of-use assets and related property in connection with vacated leases during the year,
 and $1.9 million primarily related to the write-off of a discontinued IT project in the third quarter of 2022. Impairment charges for the year ended December 31, 2021 were comprised primarily of $2.0 million related to right-of-use
 assets and related property in connection with leases that were vacated during the second quarter.

(g) <br> In addition to its scheduled payments, on June 23, 2022 and October 26, 2022, the Company made optional prepayments of $50.0 million, totaling $100.0 million, to reduce interest costs, and
 incurred prepayment premiums of $1.0 million pursuant to the Term Loan Agreement. As a result of the early prepayments, debt issuance costs of $1.4 million and $1.3 million were written off in the second and fourth quarters of 2022,
 respectively. The prepayment premiums and the write-off of debt issuance costs are included as loss on early extinguishment of debt in the consolidated statements of operations.

(h) <br> The gain on lease termination for the year ended December 31, 2022 was primarily a result of the early termination of the lease for one of the Company's corporate offices, recognized in the
 second quarter of 2022.

(i) <br> Applicant tracking system costs were related to the Company's project to replace its legacy system supporting its travel nurse staffing business. These costs are reported in selling,
 general and administrative expenses on the consolidated statement of operations and included in corporate overhead in segment data.

(j) <br> Adjusted EPS, a non-GAAP financial measure, is defined as net income (loss) attributable to common stockholders per diluted share before the diluted EPS impact of acquisition and
 integration-related costs, restructuring (benefits) costs, legal settlements and fees, impairment charges, gain or loss on derivative, loss on early extinguishment of debt, gain or loss on sale of business, applicant tracking system
 costs, and nonrecurring income tax adjustments. Adjusted EPS is not and should not be considered a measure of financial performance under GAAP. Management presents Adjusted EPS because it believes that Adjusted EPS is a useful
 supplement to its reported EPS as an indicator of operating performance. Management believes it provides a more useful comparison of the Company's underlying business performance from period to period and is more representative of the
 future earnings capacity of the Company. Quarterly non-GAAP adjustment may vary due to rounding.

(k) <br> Non-recurring income tax adjustment for the year ended December 31, 2021 reflected the reversal of the majority of the valuation allowance on deferred tax assets, as well as the
 establishment of a valuation allowance related to a state rate change as a result of the WSG acquisition.

(l) <br> Segment data is provided in accordance with the Segment Reporting Topic of the Financial Accounting Standards Board Accounting Standards Codification.

(m) <br> Contribution income is defined as income (loss) from operations before depreciation and amortization, acquisition and integration-related costs, restructuring (benefits) costs, legal
 settlement charges, impairment charges, and corporate overhead. Contribution income is a financial measure used by management when assessing segment performance.

(n) <br> Corporate overhead includes unallocated executive leadership and other centralized corporate functional support costs such as finance, IT, legal,

(o) <br> Gross profit is defined as revenue from services less direct operating expenses. The Company's gross profit excludes allocated depreciation and amortization expense. Gross profit margin is
 calculated by dividing gross profit by revenue from services.

(p) <br> FTEs represent the average number of Nurse and Allied Staffing contract personnel on a full-time equivalent basis.

(q) <br> Average revenue per FTE per day is calculated by dividing the Nurse and Allied Staffing revenue, excluding permanent placement, per FTE by the number of days worked in the respective
 periods.

(r) <br> Days filled is calculated by dividing the total hours invoiced during the period, including an estimate for the impact of accrued revenue, by 8 hours.

(s) <br> Revenue per day filled is calculated by dividing revenue as reported by days filled for the period presented.

## Contacts
Cross Country Healthcare, Inc. <br> William J. Burns, 561-237-2555 <br> Executive Vice President & Chief Financial Officer <br> wburns@crosscountry.com

**** 

<br> **** 

<br> **** <br>